Connor, Clark & Lunn Investment Management Ltd. Kodiak Sciences Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$3.01 - $7.45 $143,059 - $354,083	47,528 New	47,528 $249,000
Q3 2023 Nov 13, 2023	SELL	$1.8 - $7.49 $74,302 - $309,179	-41,279 Reduced 40.66%	60,234 $108,000
Q2 2023 Aug 10, 2023	BUY	$4.3 - $9.48 $111 - $246	26 Added 0.03%	101,513 $700,000
Q1 2023 May 09, 2023	BUY	$4.81 - $8.88 $78,734 - $145,356	16,369 Added 19.23%	101,487 $629,000
Q4 2022 Feb 10, 2023	BUY	$6.52 - $8.05 $9,147 - $11,294	1,403 Added 1.68%	85,118 $609,000
Q3 2022 Nov 10, 2022	BUY	$7.57 - $12.5 $419,446 - $692,612	55,409 Added 195.75%	83,715 $648,000
Q2 2022 Aug 05, 2022	BUY	$5.04 - $9.48 $76,945 - $144,731	15,267 Added 117.09%	28,306 $216,000
Q1 2022 May 12, 2022	BUY	$7.09 - $89.45 $92,446 - $1.17 Million	13,039 New	13,039 $101,000
Q2 2021 Aug 12, 2021	SELL	$77.2 - $126.54 $226,582 - $371,394	-2,935 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$110.45 - $164.47 $324,170 - $482,719	2,935 New	2,935 $333,000

Others Institutions Holding KOD

# of Institutions

Shares Held

39M

Call Options Held

6.5K

Put Options Held

5.8K

Baker Bros. Advisors LP New York, NY

17.3M
Shares

$151 Million
0.48% of portfolio
Black Rock Inc. New York, NY

3.85M
Shares

$33.7 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.95M
Shares

$17.1 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

1.69M
Shares

$14.7 Million
0.0% of portfolio
Iconiq Capital, LLC San Francisco, CA

1.02M
Shares

$8.9 Million
0.06% of portfolio

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account